Combined Candida dubliniensis and Candida albicans Keratitis following a Chemical Injury by Torosian, Justin & Mauger, Thomas
Faculty & Staff Scholarship 
2019 
Combined Candida dubliniensis and Candida albicans Keratitis 
following a Chemical Injury 
Justin Torosian 
Thomas Mauger 
Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications 
Case Report
Combined Candida dubliniensis and Candida albicans Keratitis
following a Chemical Injury
Justin Torosian and Thomas Mauger
West Virginia University Eye Institute, 1 Medical Center Drive, Morgantown, WV 26506, USA
Correspondence should be addressed to Justin Torosian; justin.torosian@wvumedicine.org
Received 5 March 2019; Accepted 28 April 2019; Published 13 May 2019
Academic Editor: Alexander A. Bialasiewicz
Copyright © 2019 Justin Torosian and Thomas Mauger. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Candida dubliniensis is an uncommon source of ocular infections and has only been reported in a single previous case of keratitis.
This report documents the course of a combined Candida dubliniensis and Candida albicans keratitis following a chemical injury.
Antifungal sensitivities of the two different Candida species are also demonstrated.
1. Introduction
Fungal keratitis is a challenging clinical condition. The diag-
nosis and initiation of appropriate treatment may be delayed
due to the insidious nature of the disease. Once identification
of the organism is obtained and specific treatment is initiated,
the course of therapy is often prolonged and clinical outcome
may be poor. Fungal keratitis may be caused by either
filamentous or yeast species. Filamentous fungi are more
commonly associated with refractive contact lens wear and
ocular trauma while yeasts are more commonly encountered
in cases of chronic ocular surface disease [1, 2].
2. Case Presentation
A43-year-old female presented to the emergency department
with a history of a liquid chemical exposure to the right
eye with a household liquid cleaner containing 6% sodium
hypochlorite. Examination demonstrated a central 5mm
corneal epithelial defect and diffuse conjunctival injection.
The corneal stroma was edematous. The eye was treated
with topical atropine 1% BID, prednisolone acetate 1% QID,
tobramycin-dexamethasone ointment QHS, ofloxacin QID,
doxycycline 100mg by mouth BID, vitamin C 1 tab by mouth
daily, and preservative-free artificial tears QID. The patient
was seen two days later and a 3mm central stromal infiltrate
was noted. Fortified vancomycin 50mg/ml and tobramycin
15mg/ml were added topically every hour while awake.
The patient was referred to our clinic two days later and
found to have a 3mm anterior stromal infiltrate with fluffy
borders with an overlying 5mm epithelial defect consistent
with infectious keratitis. A one millimeter hypopyon was
present (Figure 1). The cornea was cultured for bacteria and
fungus. All steroid containing medications were stopped.
Cultures were negative. The cornea remained unchanged
over the next week. The patient was taken to surgery for a
corneal biopsy, repeat corneal cultures, cryotherapy, and a
conjunctival flap. These cultures grew Candida dubliniensis
and Candida albicans. Sensitivities to antifungal agents were
obtained (Table 1).
The eye was treated with hourly topical natamycin 5% and
the infection resolved over the next three weeks (Figure 2).
She is awaiting a corneal transplant due to resultant corneal
opacity.
3. Discussion
To our knowledge, C. dubliniensis has been described only
once previously in the literature as a cause of fungal keratitis
and never in combination with C. albicans. In this previ-
ous case, the patient’s condition worsened despite topical
antifungal therapy and required cryotherapy, penetrating
keratoplasty, and instillation of intracameral antimicrobial
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Figure 1: Central corneal epithelial defect with stromal infiltrate and
hypopyon.
Table 1: Anti-Fungal Susceptibilities.
Anti-Fungal Candida albicans Candida dubliniensis
MIC SUSCEPTIBILITY MIC SUSCEPTIBILITY
(mcg/mL) (mcg/mL)
5 Flucytosine 0.5 0.06
Amphotericin B 0.5 0.225
Caspofungin 0.06 0.12
Fluconazole 0.25 0.12
Itraconazole 0.12 0.03
Voriconizole 0.008 0.008
and antifungal agents, as well as partial conjunctival flap
placement [3].
C. dubliniensis was first designated as a unique organism
in the United Kingdom in 1995, where it was identified as a
causative agent of oral candidosis [4]. More recently, it has
been identified as an uncommon cause of fungemia in cancer
patients undergoing treatment, though it remains far rarer
than various other candida species [5].
Regarding ocular involvement, C. dubliniensis has been
known to be a potential causative organism of endophthalmi-
tis, described multiple times in the ophthalmology literature
in North America since 2012 [6–8]. In this case presentation,
multiple aspects of the clinical presentation as well as the
innate properties of C. dubliniensis become of interest. C.
dubliniensis is a novel cause of fungal keratitis that can be
difficult to identify and treat but is felt to be less virulent than
C. albicans and generally susceptible to available antifungal
therapies.
C. dubliniensis has been shown to produce germ tubes
and chlamydospores, which has typically been thought of as
a property of C. albicans. However, this novel species has
been shown to be less robust on warmer temperature cultures
[4]. It is interesting that both C. albicans and C. dubliniensis
were shown to have grown in this patient. Furthermore, the
particular culture of C. dubliniensis isolated was found to
be less susceptible to caspofungin, but more susceptible to
5 flucytosine, amphotericin B, fluconazole, and itraconazole,
and equally susceptible to voriconazole compared to the C.
albicans isolate.
In vitro, C. dubliniensis has been shown to develop resist-
ance to fluconazole in a multifactorial fashion similar to C.
Figure 2: Corneal ulcer after Cryo treatment and conjunctival flap.
albicans, including both upregulation of efflux transporters
and mutations in the gene encoding for lanosterol demethy-
lase [9]. Furthermore, C. dubliniensis has been shown to be
less virulent than C. albicans, which has been postulated
maybe in part due to lower efficiency in hyphae formation
[10]. Interestingly, recent literature has illuminated that C.
dubliniensis hyphae formation is limited in nutrient-rich
media due to changes in expression of transcriptional regu-
latory protein UME6 [11].
Of interest, as opposed to the first reported case of C.
dubliniensis keratitis, our patient had both C. dubliniensis
and C. albicans isolated in the corneal biopsy culture. The
previously reported case in the literature was referred to
the authors for nonhealing corneal ulcer, but the initial
mechanism of injury is unclear. In this case, the initial injury
to the eye was a severe chemical burn from an alkaline
solution, sodium hypochlorite. It is reasonable to consider
that the severe disruption of corneal architecture allowed for
the growth of multiple infectious organisms. Furthermore,
it begs the question of how many cases of fungal keratitis
first begin as multiorganism infections. It is unclear how
commonly multiple candidal species coexist in other modes
of infection; however, C. dubliniensis and C. albicans have
been shown to do so in oral samples taken from children
with dental caries [12]. Previously, murine models have
shown an inability for C. dubliniensis to cause keratitis as a
single organism in immunocompetent mice. However, there
was an ability to cause keratitis in immunocompromised
models [13]. Perhaps the severe chemical injury in our patient
provided a relative lack of blood flow and therefore created
isolation from the body’s typical immune response.
Of note, there are several limitations to this case study.
First is that the organisms were detected and isolated by
corneal culture. Perhaps in the future, additional collateral
information including histology or sampling of other sites,
including the mouth, nares, and any eye medications the
patient may have used, would be of interest. Finally, given the
ubiquitous nature of various candida species, the possibility
of a culture contaminant must be considered.
Fortunately, the previous reported case of C. dubliniensis
keratitis had a positive outcome following instillation of
intracameral antifungals and antibiotics as well as penetrating
keratoplasty. Indeed, although C. dubliniensis keratitis is an
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uncommon cause of fungal keratitis, it tends to be less
virulent of a species and remains largely sensitive to common
antifungal agents.
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